New treatments for age-related macular degeneration

Lancet

Volumn 370, Issue 9597, 2007, Pages 1481-

  Wagle, Ajeet M ^a   Yeo, Tun Kuan ^a   Eong, Kah Guan Au ^a  

^a ALEXANDRA HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BEVACIZUMAB; CAROTENOID; PEGAPTANIB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR;

AFRICA; ASIA; BLINDNESS; CIGARETTE SMOKING; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; LETTER; LIFESTYLE MODIFICATION; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; UNITED KINGDOM; AGED; COST BENEFIT ANALYSIS; DIET; ECONOMICS; NOTE; RETINA MACULA DEGENERATION; SMOKING;

AGED; ANGIOGENESIS INHIBITORS; BLINDNESS; COST-BENEFIT ANALYSIS; DIET; HUMANS; MACULAR DEGENERATION; SMOKING;

EID: 35448952531     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61629-8     Document Type: Letter

References (5)

1. Macular degeneration, patients' groups, and pharma. Lancet 370 (2007) 194
2. Smiddy W. Relative cost of a line of vision in age-related macular degeneration. Ophthalmol 114 (2007) 847-854
3. Kelly S., Thornton J., Lyratzopoulos G., Edwards R., and Mitchell P. Smoking and blindness: strong evidence for the link, but public awareness lags. BMJ 328 (2004) 537-538
4. Seddon J., Ajani U., Sperduto R., et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA 272 (1994) 1413-1420
5. Rein D., Saaddine J., Witttenborn B., et al. Cost-effectiveness of vitamin therapy for age-related macular degeneration. Ophthalmol 114 (2007) 1319-1326